February 27, 2023
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
February 21, 2023
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
February 2, 2023
Revolution Medicines to Participate in Upcoming Investor Conferences
January 3, 2023
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
December 19, 2022
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
December 7, 2022
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
November 9, 2022
Revolution Medicines to Participate in Upcoming Investor Conferences
November 7, 2022
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
November 1, 2022
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
September 22, 2022
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor